Motus GI readies for US launch of colonoscopy prep system — 4 insights

Motus GI reported a net loss of $5.7 million in the second quarter of 2019, but is readying for the inpatient commercial launch of its colonoscopy preparation system Pure-Vu.

What you should know:

1. For the quarter, Motus reported clinical results from its latest study — showing that the Pure-Vu system increased bowel preparation rates from a baseline of 38 percent to 96 percent. The Pure-Vu system is a device used during colonoscopy to clean a poorly prepared colon. The company also received FDA 510(k) clearance for the Pure-Vu and made several appointments to bolster its leadership staff.

2. Motus' next near-term milestone is the commercial launch of the Pure-Vu system. The company has not yet specified when the launch will occur.

3. For the year to date, Motus has posted a net loss of $12 million.

4. Motus has $13.8 million in assets through the second quarter and $22.95 million in assets through the year to date.

Read the entire source here.

Copyright © 2022 Becker's Healthcare. All Rights Reserved. Privacy Policy. Cookie Policy. Linking and Reprinting Policy.

 

Featured Learning Opportunities

Featured Webinars

Featured Whitepapers

Featured Podcast